Cue Biopharma (CUE) Net Cash Flow Growth (3y) (2020 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 32.17% |
| 10 | Cue Biopharma | 449.73 Mn | 422.04 Mn | - | -10.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.99% |
| Sep 30, 2025 | 24.30% |
| Jun 30, 2025 | 115.24% |
| Mar 31, 2025 | -66.57% |
| Dec 31, 2024 | -45.07% |
| Sep 30, 2024 | 33.52% |
| Jun 30, 2024 | -164.91% |
| Mar 31, 2024 | -66.93% |
| Dec 31, 2023 | -58.32% |
| Sep 30, 2023 | -46.94% |
| Jun 30, 2023 | -27.86% |
| Mar 31, 2023 | 30.42% |
| Dec 31, 2022 | 19.24% |
| Sep 30, 2022 | -92.65% |
| Jun 30, 2022 | -41.27% |
| Mar 31, 2022 | 41.21% |
| Dec 31, 2021 | -38.52% |
| Sep 30, 2021 | 40.54% |
| Jun 30, 2021 | 27.89% |
| Mar 31, 2021 | 46.37% |
| Dec 31, 2020 | -62.64% |
| Sep 30, 2020 | 71.76% |
| Jun 30, 2020 | 129.89% |
| Mar 31, 2020 | -73.12% |